Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Claritydx Prostate Blinded

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 2/3 (1)

Trial Status

Completed2
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06678828Not ApplicableEnrolling By Invitation

Clinical Utility of ClarityDX Prostate

NCT07206693Completed

Impact of PSA-based Screening on Mortality Among Men Aged 75-79: Target Trial Emulation

NCT01415375Phase 2/3CompletedPrimary

Prostate Cancer Education in African American Men

Showing all 3 trials

Research Network

Common Treatments

  • Claritydx Prostate Blinded1
  • Fruit And Vegetable Intake Education1
  • Claritydx Prostate1
  • Prostate Specific Antigen Psa1
  • Prostate Cancer Screening Education1

Active Sponsors

  • Nanostics1
  • Karolinska Institutet1
  • Temple University1

Top Investigators

Related Conditions

  • Prostate Cancer Screening2
  • Prostate Cancer2
  • Prostate Specific Antigen Screening1

Activity Timeline